ERBB2 and breast cancer: In another study, association between FASN expression and prognostic markers was analyzed in subgroups according to pathological subtypes, including triple-negative, HER2-overexpress, luminal A, and luminal B. A high expression of FASN was found to be link to poor RFS and DMFS only in patients with HER2-overexpress breast cancer (26).